(Health-NewsWire.Net, July 26, 2017 ) Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Pipeline Review H2 2017 outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type.
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin. The molecules developed by companies in Phase II Phase I and Preclinical stages are 5 4 and 5 respectively. Similarly the universities portfolio in Preclinical stages comprises 3 molecules respectively. Report covers products from therapy areas Central Nervous System and Metabolic Disorders which include indications Alzheimer's Disease Cognitive Impairment Associated With Schizophrenia (CIAS) Schizophrenia Attention Deficit Hyperactivity Disorder (ADHD) Bipolar Disorder (Manic Depression) Cognitive Disorders Cognitive Impairment Parkinson's Disease Smoking Addiction Chronic Pain Complex Regional Pain Syndrome Dementia Associated With Alzheimer's Disease Generalized Anxiety Disorder (GAD) Major Depressive Disorder Neurodegenerative Diseases Neuropathic Pain Obesity Pain Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury.
Furthermore this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.
- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities - The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects - The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles Alvotech Iceland Eli Lilly and Company Eyevensys SAS G&E Herbal Biotechnology Co Ltd GlaxoSmithKline Plc Inflamalps SA Polaris Pharmaceuticals Inc
List of Tables Number of Products under Development by Stage of Development H2 2017 Number of Products under Development by Therapy Areas H2 2017 Number of Products under Development by Indication H2 2017 Number of Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 (Contd..1) H2 2017 Number of Products under Investigation by Universities/Institutes H2 2017 Products under Investigation by Universities/Institutes H2 2017 Number of Products by Stage and Mechanism of Actions H2 2017 Number of Products by Stage and Route of Administration H2 2017 Number of Products by Stage and Molecule Type H2 2017 Pipeline by Bionomics Ltd H2 2017 Pipeline by Bristol-Myers Squibb Company H2 2017 Pipeline by CoMentis Inc H2 2017 Pipeline by Johnson & Johnson H2 2017 Pipeline by Merck & Co Inc H2 2017 Pipeline by NeuroDerm Ltd H2 2017 Pipeline by Saniona AB H2 2017 Pipeline by SK Biopharmaceuticals Co Ltd H2 2017 Pipeline by Vanda Pharmaceuticals Inc H2 2017 Dormant Products H2 2017 Dormant Products H2 2017 (Contd..1) H2 2017 Dormant Products H2 2017 (Contd..2) H2 2017 Discontinued Products H2 2017